SCHEMBL5656467

SCHEMBL5656467

NCc1csc(Cc2ccccc2)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 5/20 0.55
HDAC6 Q9UBN7 5/20 0.55
HDAC8 Q9BY41 1/20 0.49
KLKB1 P03952 1/20 0.45
KLK1 P06870 1/20 0.45
NOS1 P29475 1/20 0.45
CDK5 Q00535 1/20 0.45
CDK5R1 Q15078 1/20 0.45
ALDH1A1 P00352 3/20 0.43
RAB9A P51151 3/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
LMNA P02545 2/20 0.43
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
LTA4H P09960 1/20 0.42
NPC1 O15118 1/20 0.42
GAA P10253 1/20 0.42
ENPP2 Q13822 1/20 0.40
LOXL2 Q9Y4K0 2/20 0.40
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14493945 0.86 HDAC1 (0.48) HDAC1HDAC6HDAC8KLKB1KLK1
SCHEMBL5659797 0.82 HDAC1 (0.55) HDAC1HDAC6HDAC8NOS1CDK5
SCHEMBL10918996 0.82 HDAC1 (0.58) HDAC1HDAC6HDAC8KLKB1KLK1
SCHEMBL11364328 0.80 HDAC1 (0.47) HDAC1HDAC6HDAC8KLKB1KLK1
SCHEMBL8222179 0.79 LOXL2 (0.57) HDAC1HDAC6HDAC8KLKB1KLK1
SCHEMBL26986062 0.78 HDAC1 (0.62) HDAC1HDAC6HDAC8CDK5CDK5R1
SCHEMBL8432354 0.78 HDAC1 (0.51) HDAC1HDAC6HDAC8KLKB1NOS1
SCHEMBL8214495 0.77 NOS1 (0.65) HDAC1HDAC6NOS1SMN1; SMN2LOXL2
SCHEMBL2642915 0.76
SCHEMBL13680923 0.76 HDAC1 (0.59) HDAC1HDAC6HDAC8KLKB1KLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285563-B2 Heteroaromatic urea derivatives as VR-1 receptor modulators for treating pain MERCK SHARP & DOHME LTD. (GB) 2007-10-23 US disclosed
US-20050107388-A1 Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain MERCK SHARP & DOHME LTD. (GB) 2005-05-19 US disclosed
EP-1490340-A1 HETEROAROMATIC UREA DERIVATIVES AS VR-1 RECEPTOR MODULATORS FOR TREATING PAIN MERCK SHARP & DOHME LTD. (GB) 2004-12-29 EP disclosed
WO-2003080578-A1 HETEROAROMATIC UREA DERIVATIVES AS VR-1 RECEPTOR MODULATORS FOR TREATING PAIN MERCK SHARP & DOHME LIMITED (GB) 2003-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107388-A1 Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain ARRB1, OPRL1, CNR1 HDAC1 2476/4885HDAC6 3320/4885HDAC8 2867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.